Literature DB >> 9472094

The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.

M S Stack1, S M Ellerbroek, D A Fishman.   

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy among North American women. The vast majority of women are diagnosed after the cancer has metastasized into the peritoneum, resulting in a low 5-year survival. Because of difficulties associated with early detection of ovarian carcinoma and the invasive potential of these malignancies, a more detailed understanding of the mechanism(s) by which ovarian carcinomas metastasize may suggest novel therapeutic approaches which could impact favorably on long-term survival. Connective tissue degrading proteinases are necessary for tumor cell invasion and enzymes in the plasminogen activator (PA) and matrix metalloproteinase (MMP) families have been implicated in ovarian cancer metastasis. The goal of this review is to summarize current data regarding the role of these proteinases in ovarian carcinoma invasion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472094     DOI: 10.3892/ijo.12.3.569

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

1.  Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis.

Authors:  P Liokumovich; I Goldberg; B Davidson; W H Gotlieb; T Zahavi; G Ben-Baruch; I Reder; J Kopolovic
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  Identification of hepsin and protein disulfide isomerase A3 as targets of gelatinolytic action in rat ovarian granulosa cells during the periovulatory period.

Authors:  Katherine Rosewell; Linah Al-Alem; Feixue Li; Brian Kelty; Thomas E Curry
Journal:  Biol Reprod       Date:  2011-07-06       Impact factor: 4.285

3.  Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.

Authors:  Dimple Chakravarty; Sudipa Saha Roy; Challa Ram Babu; Rajasekhar Dandamudi; Tyler J Curiel; Pablo Vivas-Mejia; Gabriel Lopez-Berestein; Anil K Sood; Ratna K Vadlamudi
Journal:  Clin Cancer Res       Date:  2011-03-18       Impact factor: 12.531

4.  Stress hormone-mediated invasion of ovarian cancer cells.

Authors:  Anil K Sood; Robert Bhatty; Aparna A Kamat; Charles N Landen; Liz Han; Premal H Thaker; Yang Li; David M Gershenson; Susan Lutgendorf; Steven W Cole
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.

Authors:  D A Fishman; A Kearns; S Larsh; J J Enghild; M S Stack
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

6.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.

Authors:  B Davidson; I Goldberg; W H Gotlieb; J Kopolovic; G Ben-Baruch; J M Nesland; A Berner; M Bryne; R Reich
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 7.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

8.  Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.

Authors:  Brandi R Whitley; Lea M Beaulieu; Jennifer C Carter; Frank C Church
Journal:  Gynecol Oncol       Date:  2006-10-30       Impact factor: 5.482

9.  Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer.

Authors:  Udo Jeschke; Ioannis Mylonas; Christiane Kunert-Keil; Renate Stahn; Christoph Scholz; Wolfgang Janni; Christina Kuhn; Eike Schröder; Doris Mayr; Klaus Friese
Journal:  Histochem Cell Biol       Date:  2008-10-14       Impact factor: 4.304

10.  The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.

Authors:  Aparna A Kamat; Mavis Fletcher; Lynn M Gruman; Peter Mueller; Adriana Lopez; Charles N Landen; Liz Han; David M Gershenson; Anil K Sood
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.